- $49.40m
- $56.18m
- $26.49m
- 80
- 54
- 89
- 88
Annual cashflow statement for ImmuCell, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.02 | -0.078 | -2.49 | -5.77 | -2.16 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -0.527 | 0.194 | 0.295 | 0.495 | 0.234 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.532 | -1.62 | -1.83 | -2.11 | -0.407 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | 1.32 | 0.954 | -1.54 | -4.67 | 0.358 |
| Capital Expenditures | -4.07 | -2.61 | -3.98 | -1.89 | -0.466 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.5 | 1.01 | 0.011 | 0.002 | 0.004 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -2.57 | -1.6 | -3.96 | -1.89 | -0.461 |
| Financing Cash Flow Items | -0.053 | 0.002 | -0.019 | -0.082 | -0.297 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.91 | 3.88 | 1.11 | 1.75 | 2.88 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.657 | 3.24 | -4.39 | -4.81 | 2.78 |